Abiprot Select™

We have developed protocols and algorithms for target selection in our antibody programs primarily to increase potential of each target selection in our antibody programs, which goes under the name Abiprot Select™.

  • 80 % of our targets have clinically documented efficacy, and 20% are new disruptive targets with compelling scientific credentials.

Our biologics technology platform, Abiprot™, with the Abiprot Select™ approaches the development of therapeutic antibodies differently as illustrated below.